Android app on Google Play

Cantor Fitzgerald Upgrades Ventrus Biosciences (VTUS) to Buy as Oct. Catalysts Loom

August 10, 2012 1:59 PM EDT Send to a Friend
Get Alerts VTUS Hot Sheet
Price: $1.12 +0.90%

Rating Summary:
    5 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 10 | New: 7
Trade VTUS Now!
Join SI Premium – FREE
Cantor Fitzgerald upgraded Ventrus Biosciences (NASDAQ: VTUS) from Hold to Buy with a price target of $7.00 (from $5.50).

“The stock has come in since the read-out of the hemorrhoid data in June. We have re- evaluated the story (which we now view as less risky) and believe that the stock looks inexpensive here,” said analyst Irina Rivkind

“We still think that the company can get to an FDA approval of its anal fissure compound in 2014, and we do not rule out a company sale ahead of that time,” added Rivkind

Rivkind thinks the stock may experience a positive catalyst by October, when management plans to announce the outcome of FDA discussions, along with results from an independent market research study of 1,000 doctors.

For an analyst ratings summary and ratings history on Ventrus Biosciences click here. For more ratings news on Ventrus Biosciences click here.

Shares of Ventrus Biosciences closed at $3.68 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst PT Change, Upgrades

Related Entities

Cantor Fitzgerald

Add Your Comment